Keyword: FibroGen

AstraZeneca

5. Roxadustat

FibroGen's AstraZeneca-partnered anemia drug roxadustat was first approved in China. Leerink analyst Geoffrey Porges has projected sales of about $1 billion in China alone by 2025.